Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAB9QE)

• Drug Name: Nivolumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Esophageal cancer	2B70	Phase 3	[3]
Gastric adenocarcinoma	2B72	Phase 3	[3]
Malignant pleural mesothelioma	2C26.0	Phase 3	[3]
Multiple myeloma	2A83	Phase 3	[3]
Recurrent glioblastoma	2A00.00	Phase 3	[3]
Small-cell lung cancer	2C25.Y	Phase 3	[3]
Central nervous system lymphoma	2B33.5	Phase 2	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
Follicular lymphoma	2A80	Phase 2	[3]
Prostate cancer	2C82.0	Phase 2	[3]
Ovarian cancer	2C73	Phase 1/2	[3]
Pancreatic cancer	2C10	Phase 1/2	[3]
Triple negative breast cancer	2C60-2C65	Phase 1/2	[3]
Chronic myelogenous leukaemia	2A20.0	Phase 1	[3]
Renal cell carcinoma	2C90	Application submitted	[3]
Lung squamous cell carcinoma	2C25.2	Investigative	[5]

• Cross-matching ID: TTD Drug ID: DMAB9QE

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[7]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[6]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[8]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[9]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[10]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[11]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[12]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[13]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[14]
BGB-A317	DM7NJYC	Hepatocellular carcinoma	2C12.02	Phase 3	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Modulator	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
• [5] The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules. 2021 Mar 5;26(5):1392.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [8] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [12] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [13] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)